Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease.
about
Quetiapine in the treatment of psychosis in Parkinson's diseaseMonoaminergic and Histaminergic Strategies and Treatments in Brain DiseasesAntipsychotics for the management of psychosis in Parkinson's disease: systematic review and meta-analysis.A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data.Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: results of the 12 week open label extension in the PSYCLOPS trial.Antipsychotic pharmacotherapy and orthostatic hypotension: identification and management.Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part IIAntipsychotic treatments for the elderly: efficacy and safety of aripiprazole.ACT and UCH-L1 polymorphisms in Parkinson's disease and age of onset.Antipsychotic drug use in neurodegenerative disease in the elderly: problems and potential from a pharmacological perspective.Clinical aspects of palliative care in advanced Parkinson's disease.The use of antidepressant and antipsychotic drugs in elderly epilepsy patients.Course, prognosis, and management of psychosis in Parkinson's disease: are current treatments really effective?Pathophysiology and treatment of psychosis in Parkinson's disease: a review.The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia.Atypical antipsychotics in Parkinson-sensitive populations.Neuropharmacology of dopamine receptors:: Implications in neuropsychiatric diseasesClozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow upPharmacologic management of psychosis in the elderly: a critical review.Psychosis in Parkinson's disease.Combating psychosis in Parkinson's disease patients: the use of antipsychotic drugs.Recognition and management of neuropsychiatric complications in Parkinson's disease.The management of psychosis in movement disorder patients.Intervening in the neuropsychiatric features of Parkinson's disease.Management of the behavioral aspects of Parkinson's disease.Current approaches to the treatment of Parkinson's diseaseNew approaches to understanding hallucinations in Parkinson's disease: phenomenology and possible origins.Treatment of dementia with lewy bodiesSummary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease.The serotonergic system in motor and non-motor manifestations of Parkinson's disease.The role of neurotransmitters in the development of Parkinson's disease-related psychosis.Psychosis in Parkinson Disease: A Review of Etiology, Phenomenology, and Management.New Pharmacological Approaches to Treating Non-Motor Symptoms of Parkinson's Disease.A randomized controlled trial of quetiapine for psychosis in Parkinson's disease.Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial.Olanzapine treatment for dopaminergic-induced hallucinations.Incidence, prescription patterns, and determinants of antipsychotic use in patients with Parkinson's disease.Neuropsychiatric Complications of Parkinson Disease Treatments: Importance of Multidisciplinary Care.The relationship between body mass index, the use of second-generation antipsychotics, and dental caries among hospitalized patients with schizophrenia.Late (Complicated) Parkinson's Disease
P2860
Q24628941-41D86380-8580-44B9-8867-179000DAD872Q28066691-AEF27F63-492B-4CF1-9D06-ADF952E69E9BQ30489967-20F4B43B-B4C7-4889-8798-219EEFC38F94Q30667146-6A566949-A8E3-4B30-9C26-618736EEB7AFQ32052243-BC420F56-1450-4A31-96E5-4323B7375DE5Q33160283-BA4E9CC4-2892-43EB-B8F4-A67F33C9CE71Q33612521-D35E07F5-3D62-4DE5-800F-BB9456208B99Q33755676-D213A929-B55D-439B-AE44-337A10D60893Q34147672-8F3706E3-DDF2-4303-86E9-1CAC892AFB14Q34240931-24B548EE-F6FB-4144-A4E7-13E2BE05E32CQ34457767-CE60E3D0-89FB-4330-ABD5-DB15AA7B2DE4Q34570611-87727145-D441-461F-A3C2-7A7246C82A7BQ34610593-80DAF1C7-6BA9-40BA-9C02-06890748F7B1Q34610608-AB90C4D2-69EC-4357-A51E-0058A84B1C51Q34811957-ABFBCCFA-011D-46D2-BF7F-672A82F14539Q34851726-3A74B36F-3E5D-4377-8977-0E51623647F7Q35217260-C4A8D9BF-9991-451D-9168-2AC1FD09B868Q35572611-E5994DE4-2D7E-4946-A6B3-1CD0AF907F95Q35599469-2677A192-10C6-415E-A1BB-1BF09B285D2FQ35863404-48292BC2-9FAD-4E65-BBCA-27FC8AA84CE1Q36425995-E741F96A-BE03-4A0A-A2DF-FC6C333C3E46Q36673715-2E728E62-6651-46B8-929C-EC152F78A3CFQ36808034-D3E1D1A9-EA7F-4854-85DE-CF86AF3D18EAQ36847266-1EE5A212-5B95-4514-A6AB-3D4CA3083905Q36847271-C7471120-265C-4B5E-8B6B-F0BB09D1757BQ36876438-AD2979B9-8329-4118-A2CF-7C4FB4CA2AFFQ37021326-AD8F44DD-E4D5-4817-AA1B-8FC2B7702558Q37552865-6E334698-F9AE-4464-9FB8-1B11042D9C48Q38070888-863FCDF1-97E5-46F4-8107-612481F7FDBFQ38118061-7432D01F-F2C3-4424-85D2-46A34D5524B1Q38649501-63E32E48-BAED-4228-BE88-C887A2A3026BQ39004255-8DB09DFF-E78C-443C-B7E7-9528A0C5DDB5Q39323947-2C4EB31F-9043-488F-807F-6226632C3763Q41289143-A9989164-C17C-4114-8703-A553C70D5BF2Q43827133-0F051137-7439-4A96-B54A-5A43199E7BF4Q44165264-698CE167-1C25-4D8B-B0FB-622148B7BCBFQ44836147-45113F93-3C1B-42C8-A9F9-807E664D0520Q46560199-FF31A4A7-0DC5-45ED-8BB3-26AFF36C9E56Q51452415-EDF22184-CE83-4738-BDF5-89511920AB7CQ58870320-E81EA10A-C2ED-4F0B-868E-491BD7B7E269
P2860
Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease.
description
2000 nî lūn-bûn
@nan
2000 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մարտին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Atypical antipsychotics in the ...... chosis in Parkinson's disease.
@ast
Atypical antipsychotics in the ...... chosis in Parkinson's disease.
@en
type
label
Atypical antipsychotics in the ...... chosis in Parkinson's disease.
@ast
Atypical antipsychotics in the ...... chosis in Parkinson's disease.
@en
prefLabel
Atypical antipsychotics in the ...... chosis in Parkinson's disease.
@ast
Atypical antipsychotics in the ...... chosis in Parkinson's disease.
@en
P2860
P1433
P1476
Atypical antipsychotics in the ...... chosis in Parkinson's disease.
@en
P2093
Friedman JH
P2860
P304
P356
10.1002/1531-8257(200003)15:2<201::AID-MDS1001>3.0.CO;2-D
P407
P577
2000-03-01T00:00:00Z